237 related articles for article (PubMed ID: 31315829)
21. Biosimilars - terms of use.
Declerck P; Mellstedt H; Danese S
Curr Med Res Opin; 2015 Dec; 31(12):2325-30. PubMed ID: 26397731
[TBL] [Abstract][Full Text] [Related]
22. Biosimilars: Considerations for Oncology Nurses
.
Vizgirda V; Jacobs I
Clin J Oncol Nurs; 2017 Apr; 21(2):E54-E60. PubMed ID: 28315542
[TBL] [Abstract][Full Text] [Related]
23. Demystifying biosimilars: development, regulation and clinical use.
Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
[TBL] [Abstract][Full Text] [Related]
24. Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey.
Castañeda-Hernández G; Sandoval H; Coindreau J; Rodriguez-Davison LF; Pineda C
Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1035-1044. PubMed ID: 31148288
[TBL] [Abstract][Full Text] [Related]
25. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System.
Singh A; Kalaivani M; Srivastava S; Goyal RK; Gupta SK
Ther Innov Regul Sci; 2020 May; 54(3):667-680. PubMed ID: 33301154
[TBL] [Abstract][Full Text] [Related]
26. Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics.
Wright EE; Blevins TC; Reed B; Pollom RD
J Fam Pract; 2017 Apr; 66(4 Suppl):S22-S27. PubMed ID: 28375404
[TBL] [Abstract][Full Text] [Related]
27. Regulatory challenges with biosimilars: an update from 20 countries.
Kang HN; Thorpe R; Knezevic I; Casas Levano M; Chilufya MB; Chirachanakul P; Chua HM; Dalili D; Foo F; Gao K; Habahbeh S; Hamel H; Kim GH; Perez Rodriguez V; Putri DE; Rodgers J; Savkina M; Semeniuk O; Srivastava S; Tavares Neto J; Wadhwa M; Yamaguchi T
Ann N Y Acad Sci; 2021 May; 1491(1):42-59. PubMed ID: 33222245
[TBL] [Abstract][Full Text] [Related]
28. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY.
Kaiser PK; Schmitz-Valckenberg MS; Holz FG
Retina; 2022 Dec; 42(12):2243-2250. PubMed ID: 36394884
[TBL] [Abstract][Full Text] [Related]
29. [Biosimilars--opportunity or threat?].
Swierkot J
Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
[TBL] [Abstract][Full Text] [Related]
30. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know.
Strober BE; Armour K; Romiti R; Smith C; Tebbey PW; Menter A; Leonardi C
J Am Acad Dermatol; 2012 Feb; 66(2):317-22. PubMed ID: 22243723
[TBL] [Abstract][Full Text] [Related]
31. How to select a nanosimilar.
Astier A; Barton Pai A; Bissig M; Crommelin DJA; Flühmann B; Hecq JD; Knoeff J; Lipp HP; Morell-Baladrón A; Mühlebach S
Ann N Y Acad Sci; 2017 Nov; 1407(1):50-62. PubMed ID: 28715605
[TBL] [Abstract][Full Text] [Related]
32. Pharmacovigilance and biosimilars: considerations, needs and challenges.
Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
[TBL] [Abstract][Full Text] [Related]
33. Iraqi regulatory authority current system and experience with biosimilars.
Al-Kinani KK; Ibrahim MJ; Al-Zubaidi RF; Younus MM; Ramadhan SH; Kadhim HJ; Challand R
Regul Toxicol Pharmacol; 2020 Nov; 117():104768. PubMed ID: 32861742
[TBL] [Abstract][Full Text] [Related]
34. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice.
Cohen AD; Wu JJ; Puig L; Chimenti S; Vender R; Rajagopalan M; Romiti R; de la Cruz C; Skov L; Zachariae C; Young HS; Foley P; van der Walt JM; Naldi L; Prens EP; Blauvelt A
Br J Dermatol; 2017 Dec; 177(6):1495-1502. PubMed ID: 28646580
[TBL] [Abstract][Full Text] [Related]
35. Regulatory evaluation of biosimilars throughout their product life-cycle.
Kang HN; Knezevic I
Bull World Health Organ; 2018 Apr; 96(4):281-285. PubMed ID: 29695884
[TBL] [Abstract][Full Text] [Related]
36. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
37. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
[TBL] [Abstract][Full Text] [Related]
38. What are biosimilars and are they important?
Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
[TBL] [Abstract][Full Text] [Related]
39. The challenge of biosimilars.
Mellstedt H; Niederwieser D; Ludwig H
Ann Oncol; 2008 Mar; 19(3):411-9. PubMed ID: 17872902
[TBL] [Abstract][Full Text] [Related]
40. Science of Biosimilars.
Harvey RD
J Oncol Pract; 2017 Sep; 13(9_suppl):17s-23s. PubMed ID: 28898589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
